Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Respiratory

Set Alert for Respiratory

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: novel BMS drug shows promise in IPF; Novo’s oral semaglutide compares well with injectable in weight loss; Teva looks to innovative brands to return to growth; US setback for Intercept’s NASH drug; and India’s improving environment for clinical trials.

Clinical Trials Commercial

Arrowhead’s RNAi Gaining Momentum In Heart And Lung Targets

Arrowhead has spent years in the shadows of rivals Alnylam and Ionis, but could make its mark with new ways to target cardiovascular and lung disease using RNA interference.

Companies Clinical Trials

BMS Trumpets Breakthrough For Phase III-Bound IPF Drug

Bristol Myers Squibb believes LPA1 receptor inhibition is the best approach to meet the urgent need for well tolerated new pulmonary fibrosis treatment options that can improve symptoms and address the underlying cause of disease.

Respiratory Clinical Trials

Sanofi’s Dupixent Has Greater Benefit In COPD Patients With Higher Type II Inflammation

The IL-4/IL-3 inhibitor attained a greater reduction in exacerbations in patients with a higher level of a biomarker for type 2 inflammation according to complete pivotal data, but questions remain on the timing of regulatory filings.

Clinical Trials Respiratory

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: strong growth in blockbuster ranks in 2022; Lilly’s donanemab slow cognitive decline; FDA approves first RSV vaccine; Pfizer anticipates revenue bolus from vaccines; and Astellas buys into ophthalmology.

Approvals Biologics

Sanofi Sees Dupixent As Just The Start Of COPD Transformation

Dupixent’s surprise success in COPD is welcome news, but it remains uncertain whether regulators will demand a second study readout before filing. In the meantime, Sanofi highlighted another promising late-stage candidate for the hard-to-treat disease during its Q1 results.

Sales & Earnings Clinical Trials

GSK Sees Blockbuster Chronic Cough Opportunity With $2bn Bellus Buyout

GSK has unveiled another targeted acquisition – of Bellus – that it hopes will bolster its presence in specialist respiratory medicine.

M & A Companies

Aer To Address Unmet Need In Mucus Plug-High COPD

The US biotech has closed a financing round aimed at advancing its novel mucolytic agent for a subtype of COPD with the hopes of tapping into a market of five million patients in the US alone.

Companies Financing

Bavarian Nordic Comes Up On The Rails In RSV Race

GSK and Pfizer are both likely to get FDA approval for their respiratory syncytial virus products shortly but Bavarian Nordic is progressing well with its differentiated five RSV-specific antigen jab.

Vaccines Clinical Trials

GSK And Takeda Boost Arrowhead’s Coffers, But In-House Results Crucial To Gene Silencing Platform

Arrowhead is expecting a flurry of early-stage results from its in-house pipeline, including in lung diseases, where gene silencing platforms have so far struggled to reach, as it banks two recent milestone payments.

Cardiovascular Respiratory

Dupixent Succeeds Where Other Biologic Drugs Failed – In COPD

Sanofi and Regeneron could be poised to add another blockbuster indication to the IL-4/IL-13 inhibitor, for chronic obstructive pulmonary disease.

Respiratory Inflammation

Chiesi Returns To Respiratory Roots With Affibody Pact

A busy start to the year sees the Italian firm adding to its respiratory portfolio by gaining access to the Swedish biotech’s investigational inhaled treatments.

Respiratory Deals
See All
UsernamePublicRestriction

Register